- Home
- LYEL
as of 03-05-2026 3:57pm EST
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 490.1M | IPO Year: | 2021 |
| Target Price: | $25.00 | AVG Volume (30 days): | 95.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.38 | EPS Growth: | -40.86 |
| 52 Week Low/High: | $0.39 - $45.00 | Next Earning Date: | N/A |
| Revenue: | $61,000 | Revenue Growth: | -53.08% |
| Revenue Growth (this year): | -62.38% | Revenue Growth (next year): | N/A |
| P/E Ratio: | -2.84 | Index: | N/A |
| Free Cash Flow: | -162858000.0 | FCF Growth: | N/A |
AI-Powered LYEL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Lyell Immunopharma Inc. (LYEL)
Chief Operating Officer
Avg Cost/Share
$23.39
Shares
1,236
Total Value
$28,910.04
Owned After
17,795
SEC Form 4
President and CEO
Avg Cost/Share
$23.39
Shares
7,455
Total Value
$174,372.45
Owned After
74,266
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$23.39
Shares
1,671
Total Value
$39,084.69
Owned After
16,938
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$23.12
Shares
109
Total Value
$2,520.08
Owned After
17,795
SEC Form 4
President and CEO
Avg Cost/Share
$23.12
Shares
438
Total Value
$10,126.56
Owned After
74,266
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$23.12
Shares
147
Total Value
$3,398.64
Owned After
16,938
SEC Form 4
VP, Corporate Controller
Avg Cost/Share
$23.12
Shares
254
Total Value
$5,872.48
Owned After
15,637
SEC Form 4
VP, Corporate Controller
Avg Cost/Share
$32.32
Shares
936
Total Value
$30,251.52
Owned After
15,637
SEC Form 4
VP, Corporate Controller
Avg Cost/Share
$38.67
Shares
1,136
Total Value
$43,929.12
Owned After
15,637
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hill Stephen J. | LYEL | Chief Operating Officer | Feb 11, 2026 | Sell | $23.39 | 1,236 | $28,910.04 | 17,795 | |
| Seely Lynn | LYEL | President and CEO | Feb 11, 2026 | Sell | $23.39 | 7,455 | $174,372.45 | 74,266 | |
| Lee Gary K. | LYEL | Chief Scientific Officer | Feb 11, 2026 | Sell | $23.39 | 1,671 | $39,084.69 | 16,938 | |
| Hill Stephen J. | LYEL | Chief Operating Officer | Feb 10, 2026 | Sell | $23.12 | 109 | $2,520.08 | 17,795 | |
| Seely Lynn | LYEL | President and CEO | Feb 10, 2026 | Sell | $23.12 | 438 | $10,126.56 | 74,266 | |
| Lee Gary K. | LYEL | Chief Scientific Officer | Feb 10, 2026 | Sell | $23.12 | 147 | $3,398.64 | 16,938 | |
| Bulis Veronica Sanchez | LYEL | VP, Corporate Controller | Feb 10, 2026 | Sell | $23.12 | 254 | $5,872.48 | 15,637 | |
| Bulis Veronica Sanchez | LYEL | VP, Corporate Controller | Dec 30, 2025 | Sell | $32.32 | 936 | $30,251.52 | 15,637 | |
| Bulis Veronica Sanchez | LYEL | VP, Corporate Controller | Dec 24, 2025 | Sell | $38.67 | 1,136 | $43,929.12 | 15,637 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 12, 2025 · 100% conf.
Q3 2025 Earnings
8-K SELLNov 12, 2025 · 100% conf.
1D
+0.85%
$17.78
5D
-13.12%
$15.32
20D
-16.69%
$14.69
lyel-202511120001806952false00018069522025-11-122025-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025
Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-4050283-1300510 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
201 Haskins Way South San Francisco, California 94080 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 650 695-0677 (Former Name or Former Address, if Changed Since Last Report) Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per shareLYELNASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On November 12, 2025, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit NumberDescription
99.1Press Release Dated November 12, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lyell Immunopharma, Inc.
Date:November 12, 2025By:/s/ MARK MELTZ Mark Meltz General Counsel and Corporate Secretary
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
Q2 2025 Earnings
8-KAug 12, 2025
lyel-202508120001806952false00018069522025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025
Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-4050283-1300510 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
201 Haskins Way South San Francisco, California 94080 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 650 695-0677 (Former Name or Former Address, if Changed Since Last Report) Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per shareLYELNASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On August 12, 2025, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit NumberDescription
99.1Press Release Dated August 12, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lyell Immunopharma, Inc.
Date:August 12, 2025By:/s/ MARK MELTZ Mark Meltz General Counsel and Corporate Secretary
2025 Q1 Q1 2025 Earnings
8-K May 13, 2025
Q1 2025 Earnings
8-KMay 13, 2025
lyel-202505130001806952false00018069522025-05-132025-05-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025
Lyell Immunopharma, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-4050283-1300510 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
201 Haskins Way South San Francisco, California 94080 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 650 695-0677 (Former Name or Former Address, if Changed Since Last Report) Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per shareLYELNASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On May 13, 2025, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit NumberDescription
99.1Press Release Dated May 13, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lyell Immunopharma, Inc.
Date:May 13, 2025By:/s/ CHARLES NEWTON Charles Newton Chief Financial Officer
Compare LYEL vs Leading Stocks
See how LYEL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.